Skip to main content
SpringerLink
Log in

Pharmacogenomics and Coagulation Disorders

  • Protocol
Anticoagulants, Antiplatelets, and Thrombolytics

Part of the book series: Methods In Molecular Medicine™ ((MIMM,volume 93))

  • 500 Accesses

Abstract

The term pharmacogenetics, first introduced by Vogel in 1959 (1) is defined as the analysis of inherited factors that define an individual’s response to a drug, and generally refers to monogenetic variants that affect drug response. Pharmacogenetics refers to the monogenetic variants that affect drug response, and aims to deliver the right drug to the correct patient at the correct dosage by using DNA information. Pharmacogenomics refers to the entire library of genes that determine drug efficacy and safety. There are approx 3 billion basepairs in the human genome, which code for at least 30,000 genes. Although the majority of basepairs are identical from individual to individual, only 0.1% of the basepairs contribute to individual differences. Three consecutive basepairs form a codon that specifies the amino acids that constitute the protein, because of substantial redundancy, and two or more codons code for the same amino acid. Genes represent a series of codons that specifies a particular protein. At each gene locus, an individual carries two alleles—one from each parent. If there are two identical alleles, it is referred to as a homozygous genotype; if the alleles are different, it is heterozygous. Genetic variations usually occur as single-nucleotide polymorphisms (SNP) on average at least once every 1000 basepairs, accounting for approx 3 million basepairs distributed throughout the entire genome. Genetic variations that occur at a frequency of at least 1% in the human population are referred to as polymorphisms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vogel, F. (1959) Moderne Probleme der Humangenetick. Ergebn. Inn. Med. Klinderheilk 12, 52–125.

    Google Scholar 

  2. Evans, W. E. and Relling, M. V. (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 481–491.

    Article  Google Scholar 

  3. Mamiya, K., Ieiri, I., Shimamoto, J., et al. (1999) The effects of genetic polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717–719.

    Article  Google Scholar 

  4. McCarthy, J. J. and Hilfiker, R. (2000) The use of single-nucleotide polymorphisms maps in pharmacogenomics. Nat. Biotechnol. 18, 505–508.

    Article  PubMed  CAS  Google Scholar 

  5. Krynetski, E. Y. and Evans, W. E. (1999) Pharmacogenetics as a molecular basis of individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm. Res. 16, 342–349.

    Article  PubMed  CAS  Google Scholar 

  6. Drazen, J. M., et al. (1999) Pharmacogenetic association between ALOX5 promoter genotype and the response to asthma treatment. Nat. Genet. 22, 168–170.

    Article  PubMed  CAS  Google Scholar 

  7. Collins, F. S. (1992) Positional cloning: let’s not call it reverse anymore. Nat. Genet. 1, 3–6.

    Article  PubMed  CAS  Google Scholar 

  8. Daniel Chasman, R. and Adams, M. (2001) Predicting the functional consequences of non-synonymous single nucleotide polymorphisms: structure-based assessment of amino acid variation. J. Mol. Biol. 307, 683–706.

    Google Scholar 

  9. Manucci, P. M. (2000) The molecular basis of inherited thrombophilia. Vox Sang. 83 (Suppl. 2), 39–45.

    Google Scholar 

  10. Soria, J. M., et al. (2000) Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 95(9), 2780–2785.

    PubMed  CAS  Google Scholar 

  11. Foka, Z. J., et al. (2000) Factor V Leiden and prothrombin G20210A mutations, but no methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum. Reprod. 15(2), 458–462.

    Article  PubMed  CAS  Google Scholar 

  12. Amitrano, L., et al. (2000) Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hematology 31(2), 345–348.

    CAS  Google Scholar 

  13. Ekberg, H., et al. (2000) Factor V R506Q mutation (activated protein C resistance) is additional risk factor for early renal graft loss associated with acute vascular rejection. Transplantation 69(8), 1577–1581.

    Article  PubMed  CAS  Google Scholar 

  14. Chu, K., et al. (1996) A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J. Clin. Invest. 98(7), 1619–1625.

    Article  PubMed  CAS  Google Scholar 

  15. Oldenburg, J., et al. (1997) Missense mutation at ALA-10 in the factor IX propeptide insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br. J. Haematol. 98, 240–244.

    Article  PubMed  CAS  Google Scholar 

  16. Harbrecht, U., et al. (1997) Increased sensitivity of factor IX to phenprocoumon therapy a cause of severe bleeding. Ann. Hematol. 74 (Suppl. 2), pA106.

    Google Scholar 

  17. Stanley, T. B., et al. (1999) Amino acids responsible for reduced affinities of vitamin K dependent propeptides for the carboxylase. Biochemistry 38(47), 15,681–15,687.

    Article  PubMed  CAS  Google Scholar 

  18. Santoso, S., et al. (1999) Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 93(8), 2449–2453.

    PubMed  CAS  Google Scholar 

  19. Bray, P. F. (2000) Platelet glycoprotein polymorphisms as risk factors for thrombosis. Opin. Hematol. 7(5), 284–289.

    Article  CAS  Google Scholar 

  20. Reiner, A. P., et al. (2000) Genetic variants of platelet glycoprotein receptors and risk of stroke in younger women. Stroke 31(7), 1628–1633.

    Article  PubMed  CAS  Google Scholar 

  21. Kunicki, T. J., et al. (1997) Hereditary variation in platelet integrin a2b1 density is associated with two silent polymorphisms in the a2 gene coding sequence. Blood 89, 1939.

    PubMed  CAS  Google Scholar 

  22. Zotz, R. B., Winkelmann, B. R., Nauck, M., Giers, G., et al. (1998) Polymorphism of platelet membrane glycoprotein IIIa: human platelet antigen 1b (HPA-1b/PlA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb. Haemostasis 79, 731–735.

    CAS  Google Scholar 

  23. Williamson, L. M., Hacket, G., Rennie, J., et al. (1998) The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1,Z) as determined by antenatal screening. Blood 92, 2280–2287.

    PubMed  CAS  Google Scholar 

  24. Newman, P. J., Derbes, R. S., and Aster, R. H. (1989) The human platelet alloantibody PlA1 and PlA2, are associated with a leucine 33/proline 33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J. Clin. Investig. 83, 1778–1781.

    Article  PubMed  CAS  Google Scholar 

  25. Evans, W. E. and Relling, M. V. (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–491.

    Article  PubMed  CAS  Google Scholar 

  26. Sata, F., Sapone, A., Elizondo, G., et al. (2000) CYP3A4 allelic variants with amino acid substitution in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67, 48–56.

    Article  PubMed  CAS  Google Scholar 

  27. Sachse, C., Brockmoller, J., Bauer, S., et al. (1999) Functional significans of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47, 445–449.

    Article  PubMed  CAS  Google Scholar 

  28. Stubbins, M. J., Harries, L. W., Smith, G., et al. (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6, 429–439.

    Article  PubMed  CAS  Google Scholar 

  29. Takahashi, H., Kashima, T., Nomoto, S., et al. (1998) Comparisons between in vitro and in vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 8, 365–373.

    Article  PubMed  CAS  Google Scholar 

  30. Aithal, G. P., Day, C. P., Kesteven, P. J., et al. (1999) Association of polymorphisms in the cytochrome 450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717–719.

    Article  PubMed  CAS  Google Scholar 

  31. Relling, M. V., Hancock, M. L., Rivera, G. K., et al. (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltranferase gene locus. J. Natl. Cancer Inst. 91, 2001–2008.

    Article  PubMed  CAS  Google Scholar 

  32. Lu, Z., Zhang, R., Carpenter, J. T., et al. (1998) Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implications for 5-flourouracil-based chemotherapy. Clin. Cancer Res. 4, 325–329.

    PubMed  CAS  Google Scholar 

  33. Ando, Y., Saka, H., Asai, G., et al. (1998) UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinonectan. Ann. Oncol. 9, 845–847.

    Article  PubMed  CAS  Google Scholar 

  34. Hoffmeyer, S., Burk, O., von Richter, O., et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473–3478.

    Article  PubMed  CAS  Google Scholar 

  35. Nakagawa, K. and Ishizaki, T. (2000) Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. Pharmacol. Ther. 86, 1–28.

    Article  PubMed  CAS  Google Scholar 

  36. Oliveri, R. L., Amnesi, G., Zappia, M., et al. (1999) Dopamine-D2-receptor gene polymorphism and the risk of levodopa-induced dyskinesia in PD. Neurology 53, 1425–1430.

    PubMed  CAS  Google Scholar 

  37. Kay, M. A., Manno, C. S., Ragni, M. V., et al. (2000) Evidence for gene transfer and expression of factor IX in hemophilia B patients treated with an AAV vector. Nat. Genet. 24, 257–261.

    Article  PubMed  CAS  Google Scholar 

  38. Amezianne, N., Seguin, C., Borgel, D., et al. (2002) The −33T→C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations. Thromb. Haemostasis 88, 195–199.

    Google Scholar 

  39. Dirckx, C., Donati, M. B., and Iacovello, L. (2000) Pharmacogenetics: a molecular sophistication or a new clinical tool for cardiologist? Ital. Heart J. 1, 662–666.

    PubMed  CAS  Google Scholar 

  40. Roldan, V., Corrlal, J., Marin, F., et al. (2002) Effect of Factor XIII VAL34LEU polymorphism on thrombolytic therapy in premature Myocardial Infarction. (Letter to the Editor). Thromb. Haemostasis 88, 354–355.

    CAS  Google Scholar 

  41. Jazwinska, E. C. (2001) Exploiting human genetic variation in drug discovery and development. Drug Discovery Today 6, 198–205.

    Article  PubMed  Google Scholar 

  42. Edith Chan, A. W., Zuccotto, F., Dann, S. A., et al. (2002) Protein binding pocket chemogenomics. How bioinformatics tools can help. PharmGenomics July/August, 32–40.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Loyola University Medical Center, Maywood, IL

    Omer Iqbal

Authors
  1. Omer Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Albany College of Pharmacy, Albany, NY

    Shaker A. Mousa

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Humana Press Inc.

About this protocol

Cite this protocol

Iqbal, O. (2004). Pharmacogenomics and Coagulation Disorders. In: Mousa, S.A. (eds) Anticoagulants, Antiplatelets, and Thrombolytics. Methods In Molecular Medicine™, vol 93. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-658-4:253

Download citation

  • DOI: https://doi.org/10.1385/1-59259-658-4:253

  • Publisher Name: Springer, Totowa, NJ

  • Print ISBN: 978-1-58829-083-0

  • Online ISBN: 978-1-59259-658-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation